The Biopharmaceutical Section of the American Statistical Association (ASA) formed a Safety Monitoring Working Group to strengthen collaborations between biostatisticians and safety scientists. The task began by surveying current needs and practices regarding available statistical safety tools and methods, regulatory guidance, and processes needed to support their implementation. The goal is for biostatisticians to become fully engaged safety team members by having the necessary safety skill set including appropriate methodology, regulatory guidance and access to appropriate tools. In this publication, we will discuss our survey results that reveal current practices at 22 pharmaceutical companies and demonstrate how the survey instrument can be used to map an action plan for meeting the demand for improved quantitative safety monitoring.
US Food and Drug Administration. Final rule, investigational new drug safety reporting requirements for human drug and biologic products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Fed Regist. https://www.gpo.gov/fdsys/pkg/FR-2010-09-29/pdf/2010-24296.pdf. Published September 2010.
Council for International Organizations of Medical Sciences (CIOMS), Report of CIOMS Working Group X. Evidence Synthesis and Meta-analysis for Drug Safety. Geneva, Switzerland: WHO Press; 2016.
Council for International Organizations of Medical Sciences (CIOMS) Working Group IV. Benefit-risk balance for marketed drugs: evaluating safety signals, Geneva, Switzerland, 1998. https://cioms.ch/wp-content/uploads/2017/01/benefit-risk.pdf.
CroweBXiaHANilssonMShahinSWangWJiangQ. Program safety analysis plan: an implementation guide. In: JiangQXiaHA, eds. Quantitative Evaluation of Safety in Drug Development: Design, Analysis and Reporting. Boca Raton, FL: Chapman & Hall/CRC Biostatistics Series; 2015:55–68.
15.
BallG.Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information Part 4: One method. Contemp Clin Trials. 2011;32:S11–S17.
16.
O’NeillRT. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues on international harmonization. Stat Med. 1995;14:1117–1127.
17.
YaoBZhuLJiangQXiaHA. Safety monitoring in clinical trials. Pharmaceutics. 2013;5:94–106.
18.
International Council of Harmonization. E6 Version R2: good clinical practice guidelines. http://www.ich.org. Published 2016. Accessed April 23, 2017.
19.
GouldALLystigTCLuYFuHMaH. Methods and issues to consider for detection of safety signals from spontaneous reporting databases: a report of the DIA Bayesian Safety Signal Detection Working Group. Therapeutic Innovation & Regulatory Science. 2015;49:65–75.
20.
ClarkJAKlincewiczSLStangPE. Spontaneous adverse event signaling methods: classification and use with health care treatment products. Epidemiol Rev. 2001;23:191–210.
21.
Chuang-SteinCLeV. Recent advancements in the analysis and presentation of safety data. Drug Inform J. 2001;35:377–397.
22.
GoodmanSN. Introduction to Bayesian methods I: measuring the strength of evidence. Clin Trials. 2005;2:282–290.
23.
Chuang-SteinCXiaHA. The practice of pre-marketing safety assessment in drug development. J Biopharm Stat. 2013;23:3–25.
HallgreenCEMt-IsaSLieftuchtA; on behalf of PROTECT Benefit-Risk Group. Literature review of visual representation of the results of benefit–risk assessments of medicinal products. Pharmacoepidemiol Drug Saf. 2016;25:238–250.
29.
AmitOHeibergerRMLanePW. Graphical approaches to the analysis of safety data from clinical trials. Pharm Stat. 2008;7:20–35.
GouldL. Safety graphics. In: GouldAL, ed. Statistical Methods for Evaluating Safety in Medical Product Development. Chichester, UK: Wiley; 2015:22–65.
32.
WenSHeWEvansS. Visualization of benefit-risk assessment in medical products with real examples. In: JiangQHeW, eds. Benefit-Risk Assessment Methods in Medical Product Development. Boca Raton, FL: Chapman & Hall/CRC Biostatistics Series; 2016:197–231.
CroweBJXiaHABerlinJAWatsonDJ. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clin Trials. 2009;6:430–440.
38.
SouthworthH. Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran. Stat Med. 2014;33:2914–2923.
BateALindquistMEdwardsROrreR. A data mining approach for signal detection and analysis. Drug Saf. 2002;25:393–397.
41.
VermeerNSStrausSMantel-TeeuwisseAK. Drug-induced progressive multifocal leukoencephalopathy: lessons learned from contrasting natalizumab and rituximab. Clin Pharmacol Ther. 2015;98:542–550.
42.
LanctotKLNaranjoCA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Ther. 1995;58:692–698.
43.
KramerMS. A Bayesian approach to assessment of adverse drug reactions: evaluation of a case of fatal anaphylaxis. Drug Inf J. 1986;20:505–517.
44.
XiaHAJiangQ. Statistical evaluation of drug safety data. Therapeutic Innovation & Regulatory Science. 2014;48:109–120.
45.
JiangQXiaHA, eds. Quantitative Evaluation of Safety in Drug Development: Design, Analysis and Reporting. Boca Raton, FL: CRC Press; 2015.
46.
SpiegelhalterDAbramsKMylesP, eds. Bayesian Approaches to Clinical Trials and Health Care Evaluation. Chichester, UK: Wiley & Sons Ltd; 2004.
47.
WilsonAMThabaneLHolbrookA. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol. 2003;57:127–134.
48.
SarkerAGinnRNikfarjamA. Utilizing social media data for pharmacovigilance: a review. J Biomed Inform. 2015;54:202–212.
SouthworthH. Efficient and effective review of clinical trial safety data using interactive graphics and tables. In: KrauseAO’ConnellM, eds. A Picture Is Worth a Thousand Words: Graphics in Life Sciences. New York, NY: Springer; 2012:199–216.
US Food and Drug Administration. Guidance for industry: determining the extent of safety data collection needed in late-stage premarket and postapproval clinical investigations. https://www.fda.gov/downloads/drugs/guidances/ucm291158.pdf. Published February 2016.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
